Efgartigimod alfa (Vyvgart) for Myasthenia Gravis

Date: April 18, 2022 Issue #:  1648Summary:  Efgartigimod alfa-fcab (Vyvgart– Argenx), a first-in-class neonatal Fc receptor (FcRn) antagonist, has been approved by the FDA for IV treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive. The IV complement inhibitor eculizumab(Soliris) was approved for the same indication in 2017.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: azathioprine cyclosporine corticosteroids eculizumab efgartigimod alfa methotrexate rituximab myasthenia gravis Pyridostigmine Tacrolimus Vyvgart Source Type: research